Congress Materials – European Society for Medical Oncology (ESMO 2026)
2026 European Society for Medical Oncology | Oct 23-27 | Madrid, Spain
Adaptive dosing in phase 1 study of alpitatug satetraxetan, an actinium 225-labeled antibody targeting human Kallikrein-2 for metastatic castration-resistant prostate cancer
Pedro Barata, Russell Szmulewitz, Jeffrey Y. Wong, Luke T. Nordquist, Neeraj Agarwal, Yousef Zakharia, Daniel S. Childs, Oliver Sartor, Edward F. Attiyeh, Steven I. Max, James G. Greger, Yu Cao, Alex Yu, Josh Lauring, Michael J. Morris
This document will be available on Oct 23rd 2026
AI-Based Prediction of Metastasis-Free Survival Using MRI-Derived Radiomics for Risk Stratification in Localized Prostate Cancer
Antonio José Conde Moreno, Asunción Torregrosa Andrés, Antonio L. Gutiérrez Cardo, Guillermo Barbas, Pedro D. Rodríguez, Angel Borque Fernando, Enrique Gómez Gómez, Enrique De La Peña Zarzuelo, Jaques Planas Morin, Nicolás Feltes Benitez, Rosa María Alvarez, Miguel García Sanz, Javier Gil Moradillo, Gemma Urbanos, Anna Nogué Infante, Beatriz De Garcillan Goyoaga, Bernardo Herrera Imbroda
This document will be available on Oct 25th 2026
Amivantamab + Pembrolizumab + Carboplatin in First-Line Recurrent/Metastatic Head & Neck Squamous Cell Cancer (1L R/M HNSCC): Results From the Phase 1b/2 OrigAMI-4 Study
Paul L. Swiecicki, Aarti Bhatia, Irene Braña, Andrzej Kawecki, Michael Pogorzelski, Edith Borcoman, Kevin Harrington, Robert Metcalf, Ammar Sukari, Ranee Mehra, Tomasz Rutkowski, Hideki Tanaka, Caroline Even, Kiichiro Toyoizumi, Mark Wade, Remy B. Verheijen, Emrullah Yilmaz, Sujay Shah, William Ince
This document will be available on Oct 25th 2026
Baseline and On-Treatment Urinary Tumor DNA Molecular Residual Disease (utDNA MRD) and Clinical Response to Gemcitabine Intravesical System (Gem-iDRS) in SunRISe-1 (SR-1): Updated Analysis
Felix Guerrero-Ramos, Michiel S. van der Heijden, Andrea Necchi, Giuseppe Simone, Martin Boegemann, Joseph M. Jacob, Girish Kulkarni, Karen Urtishak, Jiarui Zhang, Jennifer Mccann, Flavia Pinho, Shalaka Hampras, Abhijit Shukla, Katherine Stromberg, Won Kim, Siamak Daneshmand
This document will be available on Oct 23rd 2026
Clinical characteristics and outcomes by consensus molecular subtype in first-line anti-EGFR–treated RAS/RAF wildtype metastatic colorectal cancer
Elena Elez Fernandez, Marcia R. Cruz-Correa, Parthiv Mahadevia, Sanjib Chowdhury, Levon Demirdjian, Filippo Pietrantonio
This document will be available on Oct 25th 2026
Clinical Validation of a Tissue-Based Next-Generation Sequencing Kit for Identifying Patients With BRCA1/2-Mutated Prostate Cancer for Niraparib + Abiraterone Acetate and Prednisone Therapy
Xiaolin Lu, Dingwei Ye, Xin Ye, Yaji Xu, Victoria Zadorozhny, Usha Singh, Xiaofang Zhuo, Lesley Farrington, Yuping Chen, Tingting Wu, Lichao Luo, Han Yang, Katherine Bell, Xuesong Lyu, Yanmei Liu, Lida Zhang, Qiong Su, Fei Shen, Longen Zhou, Flora Berisha
This document will be available on Oct 23rd 2026
Dose modifications to manage adverse events in 1L EGFR-mutated advanced NSCLC: Post hoc, exploratory analyses from the phase 3 MARIPOSA trial
Shirish Gadgeel, Byoung Chul Cho, Danny Nguyen, Nicolas Girard, Enriqueta Felip, Karen Xia, George Wang, Simon Todd, Seema Sethi, Andy L. Johnson, Maria Rosario Garcia Campelo
This document will be available on Oct 26th 2026
HCRU Time and Cost Associated With Combination Treatments in First-Line Common Epidermal Growth Factor Receptor-Mutated Advanced NSCLC (1L cEGFR NSCLC)
Raffaele Califano, Guiseppe Lo Russo, Hala Ghoz, Jefferson S. Alves, Lindsay Dearden, Amy Huang, Andy L. Johnson, Irene Luccarini, Diego L. Cortinovis
This document will be available on Oct 23rd 2026
Improving Prevention of Moderate to Severe Dermatologic Adverse Events in EGFR-Mutant Advanced NSCLC Treated With First-Line (1L) Subcutaneous (SC) Amivantamab + Lazertinib: First Results From a New COCOON Cohort
Byoung Chul Cho, Jiunn Liang Tan, Weimin Li, Soon Hin How, Cheng Ta Yang, Milena P. Mak, Farastuk Bozorgmehr, Maxwell B. Sauder, Janellen Smith, Alexander I. Spira, Jill Feldman, Jairo Simões, Tonatiuh Romero, Karen Xia, Shubin Sheng, Julian Kam, Bennett Caces, Mark Wildgust, Nicolas Girard
This document will be available on Oct 24th 2026
Indirect comparison of amivantamab with real-world therapies in recurrent/metastatichead & neck squamous cell carcinoma after immune checkpoint inhibitor and platinum-based chemotherapy
Ari Rosenberg, Kevin J. Harrington, Benoît Calderon, Muh-Hwa Yang, Aarti K. Bhatia, Irene G. Braña, Ye Guo, Amy Tang, Emrullah Yilmaz, Archan Bhattacharya, Remy B. Verheijen, Levon Demirdjian, Paul L. Swiecicki
This document will be available on Oct 26th 2026
KLK2-comPAS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of a Pasritamig Plus Best Supportive Care in mCRPC
Kim Nguyen Chi, Craig Gedye, Laurence H. Belkoff, Pedro Barata, Alice Bernard-Tessier, Julie N. Graff, Nobuaki Matsubara, Shahneen K. Sandhu, Michael Schweizer, Mark N. Stein, Gunhild Von Amsberg, Bilal A. Siddiqui, Xiao Wei, Mina Hosseini, Kassie Kramer, Fouad Moussa, Sherry Wang, Shiva Dibaj, Daria Gaut, Elena Castro Marcos
This document is available on Oct 23rd 2026
KLK2-PASenger: A Phase 3 Randomized, Open-Label Study of Pasritamig, a T-Cell-Engager Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for mCRPC
Rana R. McKay, Kai-Jie Yu, Teresa Alonso-Gordoa, Johann S. De Bono, Daniel J. George, Boris A. Hadaschik, Aaron R. Hansen, Manish R. Patel, Fred Saad, Armelle Vinceneux, Qiang Wei, Daphne Wu, Mykhailo Tatarenko, Nicky Pieters, Shiva Dibaj, Sherry Wang, Dorie Capaldi, Victor M. Villalobos, Monica Chatwal, Oliver Sartor
This document will be available on Oct 23rd 2026
MyChoice: Global study evaluating patient & physician treatment preferences in first-line metastatic common EGFR-mutated NSCLC
Andrea Ferris, Nathalie Daaboul, Benjamin A. Bleiberg, Chunxia Su, Yasushi Goto, William Nassib William Jr., Melina E. Marmarelis, Leah Phillips, Dave Bjork, Shani Shilo, Simon Fifer, Maya Joshi, Brittany Keen, Francisca Maron, Jefferson S. Alves, Michelle Hull, Ellen Janssen, Anjali Shah, Yin Wan, Wade Iams
This document will be available on Oct 26th 2026
Pathology-Linked Administrative Data Reveal Bladder Cancer Natural History and Contemporary Care: A Longitudinal Population-Based Study in Ontario
Christopher Wallis, Marian Wettstein, Raj Satkunasivam, Emily Hickey, Zoe Ibraj, Peter C. Black, Wassim Kassouf, Andrea Kokorovic, Nimira S. Alimohamed, Normand Blais, Aly-Khan Lalani, Srikala Sridhar, Marie Deault-Bonin, Brendan Osborne, Girish Kulkarni
This document will be available on Oct 23rd 2026
Perioperative Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) With Radical Prostatectomy Plus Pelvic Lymph Node Dissection (RP + PLND) vs RP + PLND Alone in Patients (Pts) with High-Risk Localized or Locally Advanced Prostate Cancer (HR LPC/LAPC): PROTEUS Substudy
Alberto Briganti, Thomas Steuber, Neal D. Shore, Martin Gleave, Alexander Kretschmer, Lisa Wetherhold, Eleni Efstathiou, David J. Cahn, Ronaldo Damião, Alexandre De La Taille, Boris A. Hadaschik, Bernardo Herrera Imbroda, Álvaro Juárez Soto, Giuseppe Simone, Zhuokai Li, Sharon A. McCarthy, Mark Wildgust, Suneel D. Mundle, Adam S. Kibel, Mary-Ellen Taplin
This document will be available on Oct 24th 2026
Prostate-Specific Antigen Response and Long-Term Outcomes in PROTEUS: Perioperative Apalutamide Plus Androgen Deprivation Therapy in Patients With High-Risk Localized/ Locally Advanced Prostate Cancer
Boris A. Hadaschik, Neal D. Shore, Eleni Efstathiou, Martin E. Gleave, Angela Lopez-Gitlitz, Alexander Kretschmer, Alberto Briganti, Axel Heidenreich, Álvaro Juárez, Guiseppe Simone, Bernardo Herrera Imbroda, Alexandre De La Taille, Geoffrey Gotto, Adam S. Kibel, Brendan Rooney, Shaozhou Ken Tian, Lisa Wetherhold, Branko Miladinovic, Sharon A. McCarthy, Mary Ellen Taplin
This document will be available on Oct 23rd 2026
Safety and Efficacy of JNJ-6143, a First-in-Class Oral AR-Targeted Regulated Induced Proximity Targeting Chimera at the Optimal Dose For Further Development in Patients With mCRPC/mAPMR, Including High-Risk Molecular Features
Benjamin Garmezy, Sheena Sahota, Judy S. Wang, Sreenivasa R. Chandana, Gerald S. Falchook, Neal D. Shore, Xin Gao, Matthew R. Smith, Joseph W. Kim, Dillon Cockrell, Charles J. Ryan, Daniel P. Petrylak, Michael J. Morris, Andrew J. Armstrong, Johann S. De Bono, Alex Yu, Katherine J. Kayser-Bricker, Eyal Attar, Lindsey Hoffman, Andrew W. Hahn
This document will be available on Oct 24th 2026
Therapeutic Decision-Making in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): The INTERACT RAND/UCLA Study on ARPi-Based Doublet and Triplet Therapies
Brigida A. Maiorano, Fabio Calabrò, Matteo Santoni, Luigi Formisano, Sabrina Rossetti, Giuseppe Fornarini, Cosimo De Nunzio, Alberto Briganti, Marco Oderda, Rolando M. D'angelillo, Giulio Francolini, Luca Triggiani, Matteo Bauckneht, Marcello Scarcia, Giuseppe Simone, Marianna Portaro, Marco J. Maruzzo
This document will be available on Oct 23rd 2026
Wearable-derived Physical Activity (PA) and Patient-reported Fatigue and Sleep Differ by Hot Flash (HF) Severity Levels During the Initial Treatment Phase (ITP) in the LIBERTAS Trial
Alicia K. Morgans, Arun A. Azad, Marco Antonio Badillo Santoyo, Dana Rathkopf, Karie Runcie, Geoffrey Gotto, Axel S. Merseburger, Alex Dos Santos, Rana Zia Ur Rehman, Sukie Shopeju, Meenakshi Chatterjee, Jingwei Li, Daniel P. Sanchez, Amitabha Bhaumik, Simon Todd, Vasanth Thirugnanam, Yanran Huo, Suneel D. Mundle, Mark Wildgust, Neeraj Agarwal
This document will be available on Oct 23rd 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.